â€œOur progress with aducanumab exemplifies our broader strategy of building a multifranchise portfolio based on our deep expertise in neuroscience," Chief Executive Michel Vounatsos said in a statement.On July 8 Biogen said it had completed submission of a biologics license application to the Food and Drug Administration to market aducanumab as a treatment for Alzheimer's disease.